Trial
NCT06025110
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
ITB-Med LLC
Collaborators
—
Condition
Diabetes Mellitus, Type 1
Intervention
TCD601
Why stopped
The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-14